The Healthy Human Global Project - Hong Kong (HHGP-Hong Kong)

Healthy Clinical Trial

Official title:

The Healthy Human Global Project - Hong Kong: A Community-based Cross-sectional Study on Genetic and Environmental Determinants of Immune Phenotype Variance in a Healthy Asian Population - Establishing a Path Towards Personalized Medicine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05174624
• Other study ID #: UW21-549
• Secondary ID: HKUCTR-2959
• Status: Completed
• Start date: July 1, 2022
• Est. completion date: September 14, 2023

Study information

• Verified date: October 2023
• Source: Centre for Immunology & Infection
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Healthy Human Global Project-Hong Kong aims to elucidate the heritable and non-heritable factors that drive immunological variance within a healthy population in Hong Kong. By gaining a deeper understanding of these parameters, a path can be paved for personalised and precision medicine, tailored for an Asian population.

Description:

The Healthy Human Global Project-Hong Kong (HHGP-Hong Kong) is built upon the Milieu Intérieur Consortium, a population-based study coordinated by the Institut Pasteur in Paris since 2011 (ClinicalTrials.gov study numbers NCT01699893 and NCT03905993). The Milieu Intérieur comprised of 1,000 healthy participants that are unrelated, and of Western European ancestry, to investigate inter-individual immunological variances by integrating intrinsic, environmental and genetic factors in innate immunity and adaptive immunity. Through the quantification of white blood cells by utilising standardised flow cytometry and correlating with sociodemographic variables, the Institut Pasteur team found that smoking, age, sex, and latent infection with cytomegalovirus, were the main non-genetic factors that affected variation in parameters of human immune cells.

The HHGP-Hong Kong will, therefore, replicate and adapt from the study design of Milieu Intérieur recruiting 1,000 healthy participants, drawn from the FAMILY Cohort, to better understand the immunological variance within the Hong Kong population. This Cohort was part of a prospective population-based study in 2007, consisting of 46,001 participants in Hong Kong. It was the first large-scale programme to understand the determinants of physical, mental, and social wellbeing in Hong Kong.

A technological platform will be developed to provide a personalized patient management strategy that takes into account individual genetics, previous infection history, resident microbiota, as well as personal lifestyle and environmental factors to define immune health.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1026
• Est. completion date: September 14, 2023
• Est. primary completion date: September 14, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Subjects considered as healthy by the investigator based on medical history, clinical examination, laboratory results and ECG (blood sampling for laboratory assessments and ECG should be done at V0 and only after signed informed consent)

2. Subjects who, according to the investigator, can and will comply with the requirements of the protocol and are available for all scheduled visits at the investigational site.

3. Healthy male or female aged between 20 and 79 (included) years

4. Self-declared Han ethnicity for 3 generations

5. Body mass index (BMI) of = 18.5 and = 27.0 kg/m²

6. Ability to give their informed consent in writing

7. Must understand spoken Cantonese and written Chinese

8. Current participants enrolled in the FAMILY Cohort or their affiliates (i.e. any individuals referred by a FAMILY Cohort participant), or Hong Kong residents.

Exclusion Criteria:

1. Participation in the last 3 months or concurrent participation in another clinical study in which the subject has been exposed to a medical intervention including but not limited to pharmaceutical product or placebo or medical device

2. First-degree relative to previously recruited individuals in the study cohort

3. For women: pregnant or breastfeeding or intending to become pregnant or peri-menopausal

3.1 Peri-menopausal women as defined by menstrual irregularity: either a change in the menstrual cycle length of more than seven days (early perimenopause) or two or more missed periods with an interval of 60 days or more between periods (late perimenopause)

4. Any physical exercise within the last 4 hours before inclusion (V1)

5. Subjects following a special diet for medical reasons as prescribed by a general practitioner or dietician (e.g. calorie-restricted or weight-loss diet for significant overweight, cholesterol-lowering diet or subjects suffering from any clinically diagnosed food allergy or intolerance)

6. Binge drinking (drinking at least 5 cans of beer, 5 glasses of table wines or 5 pegs of spirits on a single occasion), >2 episodes within 3 months before inclusion

7. Illicit drug use or substance abuse within 3 months before inclusion

8. Presence of evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to participate in the study satisfactorily.

9. Severe/chronic/recurrent pathological conditions, among them:

9.1. Past or present diagnosed cancer, lymphoma, leukaemia

9.2. Personal history of organ transplant

9.3. Congenital or acquired immune deficiency (any confirmed or suspected immunosuppressive or immunodeficient condition, including a history of HIV infection)

9.4. Personal history of auto-immune diseases requiring or having previously required treatment (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sarcoidosis, Ankylosing Spondylitis, Autoimmune Haemolytic Anaemia, Autoimmune Thrombocytopenic Purpura, Crohn's Disease, Psoriasis, Scleroderma, Wegener's Granulomatosis, Type I Diabetes, Thyroiditis etc.)

9.5. Splenectomy

9.6. Acute or chronic, clinically significant, as determined by the investigator, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests

9.7. History of clinically significant, as determined by the investigator, neurological disorder of seizures

9.8. Infectious diseases

9.8.1. Chronic/ latent infection (e.g. HIV, hepatitis B virus, hepatitis C virus, HTLV, except herpes viruses such as CMV and VZV) or current acute infection or past acute infection based on investigator's judgment within the last 3 months,

9.8.2. Presence of a rectal temperature =38.4°C, or axillary temperature =37.5°C, or intra-auricular temperature =38.4 °C, or buccal temperature =38°C on the scheduled date of inclusion,

9.8.3. Subject receiving (currently or in the last 3 months) antibiotics, intestinal, nasal or respiratory antiseptics.

9.9. Severe High Blood Pressure, defined as systolic BP=160 mmHg and/or diastolic BP=100 mmHg (2020 International Society of Hypertension Global Hypertension Practice Guidelines, grade 2 hypertension). Treated and controlled high blood pressure or documented white coat hypertension is allowed.

9.10. Type II diabetes mellitus requiring treatment with any medication. Diabetes mellitus treated by exercise and diet control only is permitted.

9.11. Chronic renal impairment as defined by Renal Insufficiency: glomerular filtration rate (GFR) <60 mL/min/1.73 m²16

9.12. Chronic bone disease as treated by bisphosphonates

9.13. Any significant disorder of coagulation or treatment with direct oral anticoagulants (DOACs) or warfarin derivatives or heparin or antiplatelet medications within 2 months preceding inclusion.

9.14. Dermatologic conditions: any current dermatological disorder that is severe enough to prevent skin biopsy (e.g. eczema, psoriasis, acute or chronic dermatitis)

9.15. Severe acute and chronic allergy

9.15.1. Severe Asthma defined as asthma that is uncontrolled despite adherence with optimized high dose inhaled corticosteroid- long-acting beta2-agonist (ICS-LABA) therapy and treatment of contributory factors, or that worsens when high dose treatment is decreased,

9.15.2. Severe food allergy, as defined by a history of giant urticaria, Quincke oedema or anaphylactic shock,

9.15.3. Severe insect bite allergy with a history of giant urticaria, Quincke oedema or anaphylactic shock,

9.15.4. Atopic dermatitis treated with medication.

10. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months before the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg/day of prednisone or equivalent for > 2 weeks (inhaled and topical steroids allowed)

11. Chronic administration of NSAIDs, including aspirin: prolonged intake (> 2 weeks) within 6 months before the study or any intake [exception for low dose aspirin: maximum 250mg/daily]

12. Receipt of any vaccination 6 weeks before the inclusion or planning to receive any vaccination during the study

13. Receipt of blood products or immunoglobulins within 3 months before the inclusion or planning to receive blood products or immunoglobulins during the study

14. Haemoglobin measurement less than 10.0 g/dL for women and less than 11.5 g/dL for men

15. Platelet count less than 120.000/mm3

16. Alanine aminotransferase (ALAT) and/or aspartate transaminase (ASAT) > 3 times the upper limit of the norm (ULN)

Related Conditions & MeSH terms

• Healthy
• Immune System and Related Disorders

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
China	HKU Centre for Immunology & Infection Research Clinic	Hong Kong

Sponsors (3)

Lead Sponsor	Collaborator
Centre for Immunology & Infection	Institut Pasteur, The University of Hong Kong

Country where clinical trial is conducted

China, 

References & Publications (8)

Aziz N, Detels R, Quint JJ, Gjertson D, Ryner T, Butch AW. Biological variation of immunological blood biomarkers in healthy individuals and quality goals for biomarker tests. BMC Immunol. 2019 Sep 14;20(1):33. doi: 10.1186/s12865-019-0313-0. — View Citation

Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017 Jan;17(1):21-29. doi: 10.1038/nri.2016.125. Epub 2016 Dec 5. — View Citation

Carr EJ, Dooley J, Garcia-Perez JE, Lagou V, Lee JC, Wouters C, Meyts I, Goris A, Boeckxstaens G, Linterman MA, Liston A. The cellular composition of the human immune system is shaped by age and cohabitation. Nat Immunol. 2016 Apr;17(4):461-468. doi: 10.1038/ni.3371. Epub 2016 Feb 15. Erratum In: Nat Immunol. 2021 Feb;22(2):254. — View Citation

Delhalle S, Bode SFN, Balling R, Ollert M, He FQ. A roadmap towards personalized immunology. NPJ Syst Biol Appl. 2018 Feb 6;4:9. doi: 10.1038/s41540-017-0045-9. eCollection 2018. — View Citation

Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepanovic P, Hammer C, Jonsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M, Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M, Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML; Milieu Interieur Consortium. Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nat Immunol. 2018 Mar;19(3):302-314. doi: 10.1038/s41590-018-0049-7. Epub 2018 Feb 23. Erratum In: Nat Immunol. 2018 May 3;: — View Citation

Thomas S, Rouilly V, Patin E, Alanio C, Dubois A, Delval C, Marquier LG, Fauchoux N, Sayegrih S, Vray M, Duffy D, Quintana-Murci L, Albert ML; Milieu Interieur Consortium. The Milieu Interieur study - an integrative approach for study of human immunological variance. Clin Immunol. 2015 Apr;157(2):277-93. doi: 10.1016/j.clim.2014.12.004. Epub 2015 Jan 3. — View Citation

Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ, Narayanan M, Golding H, Moir S, Dickler HB, Perl S, Cheung F; Baylor HIPC Center; CHI Consortium. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell. 2014 Apr 10;157(2):499-513. doi: 10.1016/j.cell.2014.03.031. Erratum In: Cell. 2014 Jul 3;158(1):226. — View Citation

Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001 Sep;2(9):777-80. doi: 10.1038/ni0901-777. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Factors underlying immunological variance within the general healthy population	To identify factors (genetic, immunology and environmental) that contributes to the observed heterogeneity in immune responses (individual and population levels)	Through study completion, an average of 1 year
Primary	Naturally occurring variability of human response	To characterise the naturally occurring variability of human response using whole genome sequencing and single nucleotide polymorphisms (SNPs) haplotyping	Through study completion, an average of 1 year
Primary	Stimulated cytokine/chemokine measurement	To determine and measure cytokine/chemokine stimulated by 16 pattern-recognition receptors agonists (PRR agonists) or immune stimulators	Through study completion, an average of 1 year
Primary	Characterisation of commensal airway and gut microbiota	To characterise commensal microbiota (nasopharyngeal swab and stool samples) in the study population	Through study completion, an average of 1 year
Primary	Metagenomic architecture of faecal and nasal samples	To evaluate the metagenomic architecture of the population based on sequence analysis of bacterial, fungal and viral populations in faecal and nasal samples	Through study completion, an average of 1 year
Primary	Immune response and nutrition association	To associate immune response with nutrition data	Through study completion, an average of 1 year
Primary	Immune phenotype variance association with genetic polymorphisms and enterotype	To associate immune phenotype variance with genetic polymorphisms and enterotype	Through study completion, an average of 1 year
Primary	Heart rate variability with clinical and epidemiological data association	To associate heart rate variability with clinical and epidemiological data	Through study completion, an average of 1 year
Primary	Inflammation with physical and mental health outcome association	To associate inflammation with physical and mental health outcomes	Through study completion, an average of 1 year
Secondary	Genotype-to-phenotype associations at a mechanistic level	To determine genotype-to-phenotype associations at a mechanistic level	Through study completion, an average of 1 year
Secondary	Retrospective and prospective clinical and epidemiological data correlation with FAMILY Cohort	To correlate retrospective and prospective clinical data with and epidemiological data from the FAMILY Cohort	Through study completion, an average of 1 year
Secondary	Immune variation comparison between healthy European (Milieu Intérieur) and Asian (HHGP- Hong Kong) populations	To compare immune variation between healthy European (Milieu Intérieur) and Asian (HHGP- Hong Kong) populations	Through study completion, an average of 1 year

External Links

•   HKU Clinical Trials Registry website